title: Effect of Kangfuxin Solution on Chemo/Radiotherapy-Induced Mucositis in Nasopharyngeal Carcinoma Patients: A Multicenter, Prospective Randomized Phase III Clinical Study.
abstract: Objective. To evaluate the efficacy and safety of Kangfuxin Solution, a pure Chinese herbal medicine, on mucositis induced by chemoradiotherapy in nasopharyngeal carcinoma patients. Methods. A randomized, parallel-group, multicenter clinical study was performed. A total of 240 patients were randomized to receive either Kangfuxin Solution (test group) or compound borax gargle (control group) during chemoradiotherapy. Oral mucositis, upper gastrointestinal mucositis, and oral pain were evaluated by Common Terminology Criteria for Adverse Events (CTCAE) v3.0 and the Verbal Rating Scale (VRS). Results. Of 240 patients enrolled, 215 were eligible for efficacy analysis. Compared with the control group, the incidence and severity of oral mucositis in the test group were significantly reduced (P = 0.01). The time to different grade of oral mucositis occurrence (grade 1, 2, or 3) was longer in test group (P < 0.01), and the accumulated radiation dose was also higher in test group comparing to the control group (P < 0.05). The test group showed lower incidence of oral pain and gastrointestinal mucositis than the control group (P < 0.01). No significant adverse events were observed. Conclusion. Kangfuxin Solution demonstrated its superiority to compound borax gargle on mucositis induced by chemoradiotherapy. Its safety is acceptable for clinical application.
authors.affiliation: Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu 610041, China.
authors.forename: Yangkun
authors.initials: Y
authors.lastname: Luo
authors.affiliation: Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu 610041, China.
authors.forename: Mei
authors.initials: M
authors.lastname: Feng
authors.affiliation: Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu 610041, China.
authors.forename: Zixuan
authors.initials: Z
authors.lastname: Fan
authors.affiliation: Department of Radiation Oncology, Affiliated Cancer Hospital of Guangxi Medical University, Nanning 530021, China.
authors.forename: Xiaodong
authors.initials: X
authors.lastname: Zhu
authors.affiliation: Department of Oncology, Guizhou Cancer Hospital, Affiliated Hospital of Guiyang Medical College, Guiyang 550003, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Jin
authors.affiliation: Department of Radiation Oncology, First Affiliated Hospital of Kunming Medical University, Kunming 650032, China.
authors.forename: Rongqing
authors.initials: R
authors.lastname: Li
authors.affiliation: Department of Oncology, Affiliated Hospital of Sichuan Medical University, Luzhou 646000, China.
authors.forename: Jingbo
authors.initials: J
authors.lastname: Wu
authors.affiliation: Kelun Pharmaceutical Research Institute, Sichuan Kelun Pharmaceutical Co., Ltd., Chengdu 610071, China.
authors.forename: Xia
authors.initials: X
authors.lastname: Yang
authors.affiliation: Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu 610041, China.
authors.forename: Qinghua
authors.initials: Q
authors.lastname: Jiang
authors.affiliation: Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu 610041, China.
authors.forename: Hongfang
authors.initials: H
authors.lastname: Bai
authors.affiliation: Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu 610041, China.
authors.forename: Yecai
authors.initials: Y
authors.lastname: Huang
authors.affiliation: Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu 610041, China.
authors.forename: Jinyi
authors.initials: J
authors.lastname: Lang